Allarity Therapeutics presents AACR posters on stenoparib for colorectal cancer and ovarian cancer survival

Allarity Therapeutics, Inc.

Poster 2: stenoparib blocks WNT/β-catenin signaling and inhibits growth of colorectal cancer cell lines at clinically relevant concentrations.
Poster 1: Highest stenoparib DRP® scores are associated with enhanced overall survival in phase 2 ovarian cancer trial (NCT03878849).
CEO Thomas Jensen highlights stenoparib potential in colorectal cancer, a large area of unmet need in oncology.
DRP® companion diagnostic platform may identify patients most likely to achieve extended survival with stenoparib.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.